The Indian Practitioner

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Relative Oral Bioavailability Study of Liposomal Curcumin


Affiliations
1 Shreepad Shree Vallabh SSV Phytopharmaceuticals, Mumbai, India
2 TheraIndx LifeSciences, Pvt. Ltd., Bengaluru, India
     

   Subscribe/Renew Journal


Background: Curcumin is a naturally derived yellow polyphenolic compound from the rhizome Curcuma longa. Curcumin modulates various signalling pathways, such as Cyclooxygenase-2 (COX-2), Matrix metallopeptidases (MMPs), glutathione, protein kinase C, ATPase, nuclear Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-kb), Activator protein 1 (AP-1), P-glycoprotein 1 (P-gp), Multidrug resistance-associated proteins (MRP-1, MRP-2), Receptor tyrosine-protein kinase (ErbB2), Alpha-1-acid glycoprotein AGP), Cyclin D1 etc. Curcumin, as a free drug, has a short plasma half-life because it is rapidly metabolised in the liver. Its oral bioavailability is extremely poor, and hence Curcumin is classified as a class IV compound in the BCS system.

Materials and Methods: Authors of the current study have formulated Liposomal Curcumin and conducted a Relative Oral Bioavailability Study of Liposomal Curcumin in comparison with plain Curcumin in rats. The treatment group was given Curcumin 25% I lipo at the dose of 500 mg/kg body weight and the control group was given plain Curcumin 500 mg/ kg body weight of the rats.

Observations: Oral administration of Liposomal Curcumin showed rapid absorption (tmax =15 min) with Peak plasma concentration (Cmax), Area under Curve (AUC) and half-life (t1/2) of 42.3 ng/ml, 244 ng.h/ml and 5.5 h, respectively. In the control group, the Curcumin levels were below the level of quantitation (5.43 ng/ml).

Conclusion: This study shows that Liposomal Curcumin has higher bioavailability as compared to the marketed formulations of Curcumin. Further extensive clinical studies are needed to prove efficacy of Liposomal Curcumin in various human applications.


Keywords

Liposomal Curcumin, Bioavailability, Pharmacokinetics.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Miller JM, Thompson JK, MacPherson MB, Beuschel SL, Westbom CM, Sayan M, et al. Curcumin: a double hit on malignant mesothelioma. Cancer Prev Res (Phila). 2014; 7: 33040.

  • Hussain Z, Thu HE, Amjad MW, Hussain F, Ahmed TA, Khan S. Exploring recent developments to improve antioxidant, anti-inflammatory and antimicrobial efficacy of curcumin: A review of new trends and future perspectives. Mater Sci Eng C Mater Biol Appl. 2017; 77: 1316-26.

  • Anand, P., Sundaram, C., Jhurani, S., Kunnumakkara, A. B., and Aggarwal, B. B. Curcumin and cancer: an “old-age” disease with an “age-old” solution. CancerLett. 2008. 267, 133– 164.

  • Kunnumakkara, A.B., Anand, P., and Aggarwal, B.B. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signalling proteins. CancerLett. 2008. 269, 199–225.

  • Mohanty, C., Das, M., and Sahoo, S.K.. Emerging role of nano carriers to Increase the solubility and bioavailability of curcumin. ExpertOpin. DrugDeliv. 2012. 9, 1347–1364.

  • Cañamares, M. V., Garcia-Ramos, J. V., and Sanchez-Cortes, S. Degradation of curcumin dye in aqueous solution and on Ag nanoparticles studied by ultraviolet–visible absorption and surface-enhanced Raman spectroscopy. Appl.Spectrosc. 2006. 60, 1386–1391.

  • Kumavat, S. D., Chaudhari,Y. S., Borole, P., Mishra, P., Shenghani, K., and Duvvuri, P. Degradation studies of curcumin. Int. J.Pharm.Rev.Res 2016. 3, 50–55.

  • Wahlang, B., Pawar, Y. B., and Bansal, A. K. (2011). Identification of permeability related hurdles in oral delivery of curcumin using the CaCo-2 cell model. Eur. J. Pharm. Biopharm. 77, 275–282.

  • Liu A, Lou H, Zhao L, Fan P (2006) Validated LC/MS/MS assay for curcumin and tetrahydrocurcumin in rat plasma and application to pharmacokinetic study of phospholipid complex of curcumin. J Pharm Biomed Anal 40(3):720–727.

  • CPCSEA Guidelines for Laboratory Animal Facility. Indian Journal of Pharmacology 2003. 35: 257- 274.

  • N. M. Khalil, T. C. F. do Nascimento, D. M. Casa et al., Pharmacokinetics of curcumin-loaded PLGA and PLGAPEG blend nanoparticles after oral administration in rats. Colloids and Surfaces B: Biointerfaces, 2013. 101, 353–360.

  • Chen H, Wu J, Sun M, Guo C, Yu A, Cao F et al. N-trimethyl chitosan chloride-coated liposomes for the oral delivery of curcumin. J Liposome Res 2012;22(2):100-9.

  • Sasaki H, Sunagawa Y, Takahashi K, Imaizumi A, Fukuda H et al. Innovative Preparation of Curcumin for Improved Oral Bioavailability. Biol Pharm Bull 2011;34(5):660-5.

  • Pawar Y, Purohit H, Valicherla GR, Munjal B, Lale S, Patel SB et al. Novel lipid based oral formulation of curcumin: Development and optimization by design of experiments approach. International Journal of Pharmaceutics 2012; 436: 617–23.

  • Onoue S, Takahashi H, Kawabata Y, Seto Y, Hatanaka J, Timmermann B et al. Formulation Design and Photochemical Studies on Nanocrystal Solid Dispersion of Curcumin with Improved Oral Bioavailability. Journal of Pharmaceutical Sciences 2010;99(4): 1871-81.

  • Feng T, Wei Y, Lee RJ, Zhao L. Liposomal curcumin and its application in cancer. Int J Nanomedicine. 2017; 12: 6027-44.

  • Bisht S, Schlesinger M, Rupp A, Schubert R, Nolting J, Wenzel J, et al. A liposomal formulation of the synthetic curcumin analog EF24 (Lipo-EF24) inhibits pancreatic cancer progression: towards future combination therapies. J Nanobiotechnology. 2016; 14: 57.

  • Bingham RJ, Olmsted PD, Smye SW. Undulation instability in a bilayer lipid membrane due to electric field interaction with lipid dipoles. Phys Rev E Stat Nonlin Soft Matter Phys. 2010;81(5 pt 1):703–708.

  • Wang XY, Ishida T, Ichihara M, Kiwada H. Influence of the physicochemical properties of liposomes on the accelerated blood clearance phenomenon in rats. J Control Release. 2005;104(1):91–102.

  • Sun D, Zhuang X, Xiang X, Liu Y, Zhang S, Liu C, et al. A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol Ther. 2010; 18: 1606-14.

  • He W, Zou C, Tian Z, Tan W, Shen W, Chen J, et al. Nasopharyngeal carcinoma treated with bevacizumab combined with paclitaxel liposome plus cisplatin: a case report and literature review. Onco Targets Ther. 2017; 10:67-72.

  • Mahmud M, Piwoni A, Filipczak N, Janicka M, Gubernator J. Long-Circulating Curcumin-Loaded Liposome Formulations with High Incorporation Efficiency, Stability and Anticancer Activity towards Pancreatic Adenocarcinoma Cell Lines In Vitro. PLoS One. 2016; 11: e0167787.

  • Kitajima H, Komizu Y, Ichihara H, Goto K, Ueoka R. Hybrid liposomes inhibit tumor growth and lung metastasis of murine osteosarcoma cells. Cancer Med. 2013; 2: 267-76.

  • Ucisik MH, Kupcu S, Schuster B, Sleytr UB. Characterization of CurcuEmulsomes: nanoformulation for enhanced solubility and delivery of curcumin. J Nanobiotechnology. 2013; 11: 37.

  • Yallapu MM, Jaggi M, Chauhan SC. Curcumin nano formulations: A future nanomedicine for cancer. Drug Discov Today. 2012; 17: 71-80.

  • Storka A, Vcelar B, Klickovic U, Gouya G, Weisshaar S, Aschauer S, et al. Safety, tolerability and pharmacokinetics of liposomal curcumin in healthy humans. Int J Clin Pharmacol Ther. 2015; 53: 54-65.


Abstract Views: 300

PDF Views: 0




  • Relative Oral Bioavailability Study of Liposomal Curcumin

Abstract Views: 300  |  PDF Views: 0

Authors

Yogesh Dound
Shreepad Shree Vallabh SSV Phytopharmaceuticals, Mumbai, India
Ramesh Jayaraman
TheraIndx LifeSciences, Pvt. Ltd., Bengaluru, India

Abstract


Background: Curcumin is a naturally derived yellow polyphenolic compound from the rhizome Curcuma longa. Curcumin modulates various signalling pathways, such as Cyclooxygenase-2 (COX-2), Matrix metallopeptidases (MMPs), glutathione, protein kinase C, ATPase, nuclear Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-kb), Activator protein 1 (AP-1), P-glycoprotein 1 (P-gp), Multidrug resistance-associated proteins (MRP-1, MRP-2), Receptor tyrosine-protein kinase (ErbB2), Alpha-1-acid glycoprotein AGP), Cyclin D1 etc. Curcumin, as a free drug, has a short plasma half-life because it is rapidly metabolised in the liver. Its oral bioavailability is extremely poor, and hence Curcumin is classified as a class IV compound in the BCS system.

Materials and Methods: Authors of the current study have formulated Liposomal Curcumin and conducted a Relative Oral Bioavailability Study of Liposomal Curcumin in comparison with plain Curcumin in rats. The treatment group was given Curcumin 25% I lipo at the dose of 500 mg/kg body weight and the control group was given plain Curcumin 500 mg/ kg body weight of the rats.

Observations: Oral administration of Liposomal Curcumin showed rapid absorption (tmax =15 min) with Peak plasma concentration (Cmax), Area under Curve (AUC) and half-life (t1/2) of 42.3 ng/ml, 244 ng.h/ml and 5.5 h, respectively. In the control group, the Curcumin levels were below the level of quantitation (5.43 ng/ml).

Conclusion: This study shows that Liposomal Curcumin has higher bioavailability as compared to the marketed formulations of Curcumin. Further extensive clinical studies are needed to prove efficacy of Liposomal Curcumin in various human applications.


Keywords


Liposomal Curcumin, Bioavailability, Pharmacokinetics.

References